Résumé

Dans le traitement des effets de la ménopause, les oestrogènes ont fait leur preuve en palliant à toutes les manifestations cliniques apparentes et inapparentes de l’extinction de la fonction ovarienne [2]. Toutefois, même en association avec un progestatif, et dans une certaine mesure à cause de cette association avec un progestatif [7], les traitements substitutifs à base d’oestrogènes donnent lieu à des effets secondaires qui rendent souhaitable de disposer de solutions alternatives et incitent à développer de nouvelles formes de traitement, par exemple par le choix d’autres formes galéniques ou la mise au point de nouvelles molécules. Quelles sont donc les perspectives dans ce domaine?

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliographie

  1. 1.
    Birkhäuser MH (1988) Central and peripheral effects of vaginal estrogen therapy. In: Genazzani AR, Montemagno V, Nappi C, Petraglia F (eds) The brain and female reproduction function. Parthenon, Casterton Hall, pp 601–608Google Scholar
  2. 2.
    Christiansen C (1988) Estrogentherapy of osteoporosis. Dans: The Proceedings of a Special Symposium held at the First Congress of the International Society of Gynecological Endocrinology. In: Christiansen C (ed) New horizons in osteoporosis. Parthenon, Casterton Hall, pp 13–19Google Scholar
  3. 3.
    Clayden JR, Bell JW, Pollard P (1974) Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1: 409–412PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    David A, Don R, Tajchner G, Weissglas L (1988) Vaeralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 158: 1107–1115PubMedCrossRefGoogle Scholar
  5. 5.
    De Aloysio D, Fabiani AG, Maufoni M, Bottiglioni F (1987) Use of Org OD 14 for the treatment of climateric complaints. Maturitas [Suppl] 1: 49–65CrossRefGoogle Scholar
  6. 6.
    Delanian L (1980) Etude clinique de l’activité d’une nouvelle molécule de veralipride sur les troubles psychoneuro-végétatifs de la ménopause. Sem Hop Paris 56: 1468–1470PubMedGoogle Scholar
  7. 7.
    Don Gambrell R jr (1987) Estrogen replacement therapy — guidelines for safe use. Drug Therapy 68: 80Google Scholar
  8. 8.
    Edington RF, Chagman JP, Steinberg WM (1980) Clonidine (Dixarit) for menopausal flushing. Can Med Assoc J 123: 23–26PubMedCentralPubMedGoogle Scholar
  9. 9.
    Ginsburg J, Reilly O, Swinhoe J (1985) Effect of oral Clonidine on human cardiovascular responsiveness: a possible explanation of the therapeutic action of the drug in menopausal flushing and migraine. Br J Obstet Gynaecol 92: 1169–1175PubMedCrossRefGoogle Scholar
  10. 10.
    Holmgren PA, Lindskog M, von Schoultz B (1989) Vaginal rings for continuous lowdose release of oestradiol in the treatment of urogenital atrophy. Maturitas 11: 55–63PubMedCrossRefGoogle Scholar
  11. 11.
    Keller PJ (1988) Transdermal systems for estrogentherapy in menopause. In: Genazzani AR, Montemagno V, Nappi C, Petraglia F (eds) The brain and female reproduction. Parthenon, Casterton Hall, pp 601–609Google Scholar
  12. 12.
    Keller PJ (1988) Combined transdermal hormone therapy. In: Genazzani AR, Petraglia F, Volpe A, Facchinetti F (eds) Advances in gynaecological andocrinology. Parthenon, Carnforth, pp 651–657Google Scholar
  13. 13.
    Kicovic PM, Cortes-Prieto J, Luisi M, Milojevic S, Franchi F (1982) Placebo-controlled crossover study of effects of Org OD 14 in menopausal women. Reproduction 6: 81–91Google Scholar
  14. 14.
    Kicovic PM (1988) New steroid for the climateric syndrome. In: Gemazzani AR, Montemagno V, Nappi C, Petraglia F (eds) The brain and female reproductive function. Parthenon, Casterton Hall, pp 610–616Google Scholar
  15. 15.
    Laufer LR (1982) Effect of Clonidine on hot flashes in postmenopausal women. Obstet Gynecol 60: 583–586PubMedGoogle Scholar
  16. 16.
    Linquette M, Riviere J, Vague J (1980) Traitement non hormonal des troubles de la ménopause — étude multicentrique en double insu. Sem Hop Paris 56: 1445–1448PubMedGoogle Scholar
  17. 17.
    Lufkin EG, Carpenter PC, Ory SJ, Malkesian GD, Edmonson J-H (1988) Estrogen replacement therapy: current recommendations. Mayo Clin Proc 63: 453–460PubMedCrossRefGoogle Scholar
  18. 18.
    Metzger DA, Hammond CB (1988) Are estrogens indicated for the treatment of postmenopausal women. Drug Intell Clin Pharm 22: 493–496PubMedGoogle Scholar
  19. 19.
    Mishell DR, Moore DE, Roy S, Brenner PF, Page MA (1978) Clinical performance and endocrine profile with contraceptive vaginal ring containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 130: 55–62PubMedGoogle Scholar
  20. 20.
    Nagomani M, Kelver ME, Smith ER (1987) Treatment of menopausal hot flashes with transdermal administration of Clonidine. Am J Obstet Gynecol 156: 561–565CrossRefGoogle Scholar
  21. 21.
    Reginster JY, Denis D, Albert A, Deroisy R, Leeart MP, Fontaine MA, Franchimont P (1988) Intranasal calcitonin: a new horizon in prevention of early postmenopausal boneloss. In: Christiansen C (ed) New horizons in osteoporosis. Parthenon, Carnforth, pp 27–35Google Scholar
  22. 22.
    Riis BJ, Christiansen C, Overgaard K (1988) The effect of nasal calcitonine on postmenopausal oestoporosis. In: Christiansen C (ed) New horizons in osteoporosis. Parthenon, Carnforth, pp 37–41Google Scholar
  23. 23.
    Sandrin R, Evrard G, Adnet JJ, Wahl P, Quereux C (1980) Etude cytologique hormonale des frottis vaginaux avant et après traitement par veralipride. Sem Hop Paris 56: 1460–1464Google Scholar
  24. 24.
    Salmi T, Punnonen R (1979) Clonidine in the treatment of menopausal symptoms. Int J Gynaecol Obstet 16: 422–426PubMedGoogle Scholar
  25. 25.
    Sitruk-Ware R (1988) Editorial. Maturitas 10: 79–81PubMedCrossRefGoogle Scholar
  26. 26.
    Stevenson JC, Cush MP, Ganger KF (1988) Calcitonin and estrogen in the management of osteoporosis. In: Christiansen C (ed) New horizons in oestoporosis. Parthenon, Carnforth, pp 21–26Google Scholar
  27. 27.
    Tax L, Goorissen EM, Kicovic PM (1987) Clinical profile of Org OD 14. Maturitas [Suppl] 1: 3–13CrossRefGoogle Scholar
  28. 28.
    Treroux R, Dieulangard P, Blum A (1983) Efficacy and safety of Org OD 14 in the treatment of climateric complaints. Maturitas 5: 89–96CrossRefGoogle Scholar
  29. 29.
    Tulandi T, Lal S, Kinch RA (1983) Effect of intravenous Clonidine on menopausal flushing and luteinizing hormone secretion. Br J Obstet Gynaecol 90: 854–857PubMedCrossRefGoogle Scholar
  30. 30.
    Verbeke K, Dhout M, van de Kerckhove D (1988) Clinical and hormonal effects of long-term veralipride treatment in post-menopausal women. Maturitas 10: 225–230PubMedCrossRefGoogle Scholar
  31. 31.
    Wesel S, Bosuma WB (1983) L’alternative au traitement hormonal des bouffées vasomotrices de la ménopause: le veralipride. Sem Hop Paris 59: 596–599PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • H. J. Welti
    • 1
  1. 1.Département de Gynécologie-ObstétriqueCHUVLausanneSwiss

Personalised recommendations